Evidence map›Paper›PMID 28364518›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2017

Interaction Between Ezrin and Cortactin in Promoting Epithelial to Mesenchymal Transition in Breast Cancer Cells.

Jing He, Ge Ma, Jiayi Qian, Yichao Zhu, Mengdi Liang, Na Yao, Qiang Ding, Lin Chen, Xiaoan Liu, Tiansong Xia and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Cortactin in Epithelial-Mesenchymal Transition.Frontiers in cell and developmental biology · 2020
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Detecting the location and significance of Ezrin protein expression in hepatocellular carcinoma.International journal of clinical and experimental pathology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Jing HeDepartment of Surgical Oncology, The Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China (mainland).
Ge MaBreast Disease Center, 1st Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China (mainland).
Jiayi QianBreast Disease Center, 1st Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China (mainland).
Yichao ZhuDepartment of Physiology, Nanjing Medical University, Nanjing, Jiangsu, China (mainland).
Mengdi LiangBreast Disease Center, 1st Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China (mainland).
Na YaoBreast Disease Center, 1st Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China (mainland).
Qiang DingBreast Disease Center, 1st Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China (mainland).
Lin ChenBreast Disease Center, 1st Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China (mainland).
Xiaoan LiuBreast Disease Center, 1st Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China (mainland).
Tiansong XiaBreast Disease Center, 1st Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China (mainland).
Shui WangBreast Disease Center, 1st Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China (mainland).
Nanjing Medical University · CNJiangnan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Epithelial to mesenchymal transition (EMT) contributes to metastases in various types of tumors, and is also the key step in the breast cancer metastatic cascade. In our previous study, a mouse model containing human-derived normal breast tissue was established and allowed EMT/MET process of human breast cancer cells to be mimicked in a humanized mammary microenvironment. MATERIAL AND METHODS Two-dimensional electrophoresis (2-DE) and mass spectrometry were used to detect different proteins between parental MDA-MB-231 and its variant sub-line obtained from tumors grown in transplanted normal human breast tissue (MDA-MB-231br). We knocked down the ezrin in 2 cell lines (MDA-MB-231 and SUM1315). The migration and invasion ability was assessed. EMT markers were examined by real-time reverse transcription PCR analysis and Western blot analysis. The relationship of ezrin with cortactin was tested by tissue microarray and co-immunoprecipitation. RESULTS Proteomic analysis revealed 81 differentially expressed proteins between parental MDA-MB-231 and MDA-MB-231br. Among these proteins, the expression of ezrin and cortactin and the phosphorylation of ezrin were significantly correlated, accompanied with a group of classic EMT makers. Knockdown of ezrin reversed the expression of EMT markers and downregulated cortactin and EMT transcription factors. Ezrin silencing inhibited tumor cell migration and invasion. Breast cancer tissue microarray and immunohistochemistry showed a significant positive association between ezrin and cortactin. CONCLUSIONS These findings indicate that ezrin is correlated with cortactin in facilitating EMT in breast cancer. The interaction between ezrin and cortactin is a novel mechanism contributing to the EMT process in cancer metastases.

Indexed as

Epithelial-Mesenchymal TransitionAnimalsBreast NeoplasmsCell Line, TumorCell MovementCell ProliferationCortactinCytoskeletal ProteinsEzrinFemaleGene Knockdown TechniquesHumansMammary Neoplasms, ExperimentalMCF-7 CellsMicePrognosisCortactinCytoskeletal ProteinsEzrinTranscription Factors

Identifiers

PMID28364518
PMCPMC5386444
OpenAlexW2604084641

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.